To cite: Takeuchi T, Tanaka Y, Tanaka S, et al. Annals of the Rheumatic Diseases 2019. Published Online First: 26 July 2019. Read the full article here:
Objectives: To evaluate the efficacy and safety of the oral Janus kinase (JAK) inhibitor peficitinib versus placebo in Japanese patients with rheumatoid arthritis (RA).
Conclusion: In Japanese patients with RA and inadequate response to MTX, peficitinib demonstrated significant superiority versus placebo in reducing RA symptoms and suppressing joint destruction. Peficitinib had an acceptable safety and tolerability profile, with no new safety signals compared with other JAK inhibitors.
0 Comments